MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024
January 05 2024 - 8:00AM
Business Wire
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the
“Company”), a clinical-stage biopharmaceutical company developing
telomere-targeting immunotherapies for cancer, today announced its
participation in the Biotech Showcase™ 2024 investor
conference being held January 8-10, 2024, in San Francisco,
California. Chairman and Chief Executive Officer Vlad Vitoc, MD,
MBA will present on Tuesday, January 9, 2024, at 11:30 am PST.
Dr. Vitoc will provide an update on the Company’s lead program,
THIO, a potential first-in-class telomere targeting agent in
clinical development for the treatment of non-small cell lung
cancer (NSCLC). Exceptional preliminary efficacy data from the
ongoing THIO-101 Phase 2 trial includes an unprecedented disease
control rate (DCR) of 100% in second-line NSCLC treatment. Dr.
Vitoc will also discuss multiple value-driving Company milestones
expected in 2024 and beyond.
Conference details:
MAIA live presentation:
11:30 am PST, Tuesday, January 9, 2024
Location:
Hilton San Francisco Union Square
Registration:
Available on the conference website.
1-on-1 meetings:
Requests available upon registration.
Presentation slides:
ir.maiabiotech.com under Company Info:
Presentations
“We are delighted that MAIA Biotechnology will be joining us in
San Francisco and presenting at Biotech Showcase this year,” said
Sara Demy, CEO of Demy-Colton, producer for the event. “Biotech
Showcase is a prime opportunity for life science entrepreneurs and
investors to come together to discover the potential of innovative
technologies that will drive the future of drug discovery.”
The Biotech Showcase investor conference focuses on driving
advances in therapeutic development by providing a sophisticated
networking platform for executives and investors. The conference
takes place each year in San Francisco alongside the J.P. Morgan
Annual Healthcare Conference.
*Please note that the presentation date and time are subject to
change. Attendees can refer to the program agenda for more
information.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on
the development and commercialization of potential first-in-class
drugs with novel mechanisms of action that are intended to
meaningfully improve and extend the lives of people with cancer.
Our lead program is THIO, a potential first-in-class cancer
telomere targeting agent in clinical development for the treatment
of NSCLC patients with telomerase-positive cancer cells. For more
information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of
historical facts contained in this press release, are
forward-looking statements. Forward-looking statements are subject
to known and unknown risks, uncertainties, and other factors that
may cause our or our industry’s actual results, levels or activity,
performance or achievements to be materially different from those
anticipated by such statements. The use of words such as “may,”
“might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,”
“believe,” “estimate,” “project,” “intend,” “future,” “potential,”
or “continue,” and other similar expressions are intended to
identify forward looking statements. However, the absence of these
words does not mean that statements are not forward-looking. For
example, all statements we make regarding (i) the initiation,
timing, cost, progress and results of our preclinical and clinical
studies and our research and development programs, (ii) our ability
to advance product candidates into, and successfully complete,
clinical studies, (iii) the timing or likelihood of regulatory
filings and approvals, (iv) our ability to develop, manufacture and
commercialize our product candidates and to improve the
manufacturing process, (v) the rate and degree of market acceptance
of our product candidates, (vi) the size and growth potential of
the markets for our product candidates and our ability to serve
those markets, and (vii) our expectations regarding our ability to
obtain and maintain intellectual property protection for our
product candidates, are forward looking. All forward-looking
statements are based on current estimates, assumptions and
expectations by our management that, although we believe to be
reasonable, are inherently uncertain. Any forward-looking statement
expressing an expectation or belief as to future events is
expressed in good faith and believed to be reasonable at the time
such forward-looking statement is made. However, these statements
are not guarantees of future events and are subject to risks and
uncertainties and other factors beyond our control that may cause
actual results to differ materially from those expressed in any
forward-looking statement. Any forward-looking statement speaks
only as of the date on which it was made. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise, except as required by law. In this release, unless the
context requires otherwise, “MAIA,” “Company,” “we,” “our,” and
“us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240105333689/en/
Investor Relations Contact +1 (872) 270-3518
ir@maiabiotech.com
Maia Biotechnology (AMEX:MAIA)
Historical Stock Chart
From Apr 2024 to May 2024
Maia Biotechnology (AMEX:MAIA)
Historical Stock Chart
From May 2023 to May 2024